

Synthesis of ‘difficult’ peptide sequences: application of a depsipeptide technique to the Jung–Redemann 10- and 26-mers and the amyloid peptide A β (1–42)

Louis A. Carpino,^{a,*} Eberhard Krause,^{b,*} Calin Dan Sferdean,^a Michael Schümann,^b Heinz Fabian,^c Michael Bienert^b and Michael Beyermann^b

^aDepartment of Chemistry, University of Massachusetts, Amherst, Massachusetts 01003, USA

^bInstitute of Molecular Pharmacology, Robert-Rössle-Str. 10, 13125 Berlin, Germany

^cRobert Koch-Institut, P 13 Nordufer 20, 13353 Berlin, Germany

Received 17 May 2004; revised 26 July 2004; accepted 26 July 2004

Available online 28 August 2004


Abstract—Recently a 26-mer peptide **1** incorporating Ser and Thr was described as a ‘difficult’ sequence that could not be synthesized by standard methods. If the first Ser residue was used to incorporate a depsipeptide unit, the resulting hybrid was readily assembled. The 26-mer ester was then converted to the native peptide by an O→N acyl shift. The technique may be general for other systems containing appropriate Ser and Thr units and was demonstrated here for the case of the amyloid peptide A β (1–42). © 2004 Elsevier Ltd. All rights reserved.

In 1996 Jung and Redemann (JR)¹ reported that 26-mer **1** represented a ‘difficult’ peptide sequence in that an attempted automated assembly by standard (N-TBTU)² Fmoc-based methodology gave none of the desired peptide. On the other hand substitution of the acid fluoride-forming reagent TFFH³ for N-TBTU gave the desired peptide with a purity of approximately 40%. The published ESI-MS trace of the crude product obtained via N-TBTU showed that the major deletion peptides come within the first nine C-terminal amino acids suggesting

that even the corresponding 10-mer, **2** would probably also represent a difficult sequence and therefore an excellent short model for the testing of peptide methodology.



Previously,⁴ we have made extensive use of ACP decapeptide **3** for this purpose but this sequence is truly difficult only under demanding conditions, for example, when using a limited excess (0.5 molar equiv) of amino acid and a short coupling time (1.5 min).



As expected when assembly of **2** was examined under standard conditions (N-HBTU; 7 min preactivation; 30 min coupling; 15 min deblocking; 4 equiv excess Fmoc amino acid; 8 equiv DIEA) major deletion peptides were

Abbreviations: ACP = Acyl carrier protein decapeptide (64–75); Boc = *t*-butyloxycarbonyl; (Boc)₂O = di-*t*-butyldicarbonate; Bsmoc = 1,1-dioxobenzothiothiophene-2-ylmethyloxycarbonyl; DCM = dichloromethane; DIEA = diisopropylethylamine; DMAP = 4-(dimethylamino)pyridine; Fmoc = 9-fluorenylmethyloxycarbonyl; N-HATU = 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo-[4,5-*b*]pyridinium hexafluorophosphate 3-oxide; N-HBTU = 1-[bis(dimethylamino)methylene]-1*H*-benzotriazolium hexafluorophosphate 3-oxide; N-TBTU = 1-[bis(dimethylamino)methylene]-1*H*-benzotriazolium tetrafluoroborate 3-oxide; TFA = trifluoroacetic acid; TFFH = tetramethylfluoroformamidinium hexafluorophosphate; Trt = trityl = triphenylmethyl.

Keywords: Depsipeptides; O/N shift; Difficult sequences; Protecting groups; Bsmoc group; Amyloid peptide.

* Corresponding authors. E-mail addresses: carpino@chem.umass.edu; ekrause@fmp-berlin.de

obtained in significant amounts [Fig. 1; des-Thr (7.2%), des-Trp (15.9%), des-Phe (4.5%), des-(Trp, Thr) (8.6%), des-(Trp, Phe) (7.5%), and des-(Trp, Phe, Thr) (2.3%)].

Using an ABI 433A peptide synthesizer and standard instrument files for a 20- μ mol scale synthesis with a 5-equivalent excess of Fmoc amino acid, it was established that the deblocking difficulties commenced at amino acid number 5 (Leu) as shown in Figure 2A. Since deblocking of the Bsmoc⁵ residue is considerably faster than for the Fmoc analog, an initial attempt using **2** as a test sequence involved a comparison of assembly via Fmoc and Bsmoc chemistry. As expected the latter led to a more effective synthesis, for example, with

5 equiv of protected amino acid, 10 equiv of DIEA as base, and 5 equiv of N-HATU as coupling reagent with a 30s preactivation period and 2 \times 4 min for deblocking,⁶ Fmoc and Bsmoc assembly led to decapeptide **2** in yields of 40.7% and 48.8%, respectively.

Other interesting results emerged upon a careful examination of the LC–MS traces for the Fmoc synthesis (Fig. 1A–C, Supplementary data). A significant peak was observed at 33.9 min, which exhibited the same molecular weight as the desired 10-mer **2** and separated from it by only 2.4 min, thus suggesting that it represented an epimer arising from loss of configuration at one of the constituent amino acids during activation. Of the




Figure 1. UV chromatogram (220 nm) of crude peptide **2** obtained via standard Fmoc/N-HBTU chemistry. For LC details see Supplementary data.





Figure 2. UV monitoring traces for the assembly of peptide **2** on an ABI 433A peptide synthesizer. (A) Fmoc chemistry monitored at 301 nm; (B) Bsmoc chemistry, monitored at 310 nm. For details see Supplementary data.



which accounts for the difficulty of synthesizing the JR sequence, which is known to begin at amino acid number 5, is overcome by the presence of the ester linkage built into positions 6–7 or 7–8. The ammonium hydroxide-induced O→N shift for the authentic depsipeptide was examined in the case of **9** and **10**, with reversal occurring more readily for the latter.


In view of the tendency for serine to undergo loss of configuration, as noted above, it was not unusual that coupling of the serine residue to the threonine hydroxyl unit in the synthesis of **10** via the DCC/DMAP technique was accompanied by extensive epimerization (up to 22.5%). Considering that synthetic difficulties in the synthesis of **2** appear to have been avoided in the syntheses of **9** and **10** it was expected that one could merely continue the assembly to the end of the 26-mer sequence and then effect the O→N shift and thereby obtain the native amide sequence in good yield. In order to avoid loss of configuration at serine this was done for sequence **9** and in fact an excellent synthesis of the 26-mer resulted. The progress of the final step (O→N shift) is shown in Figure 3.

This new method may well prove to be applicable to any difficult sequence for which serine or threonine units are found at appropriate positions.¹¹ It may be noted that

these are precisely the systems for which the ‘pseudoproline’ method of Mutter et al.¹² for the synthesis of difficult sequences was designed. It was shown as part of the present work that the Mutter technique, involving the simultaneous introduction of Ile²² and Ser²³ via the dipeptide Fmoc-Ile-Ser($\psi^{\text{Me,Me}}$ pro)-OH also provided an excellent route to the full 26-mer **1**.

With both depsipeptide and amide forms of 26-mer **1** available, pure samples were obtained and subjected to IR studies in order to characterize the structural effects presumably responsible for the facile synthesis of the ester form. In the IR spectrum the amide form, upon solution in D₂O, shows the characteristic band at 1621 cm⁻¹, which indicates the presence of significant amounts of intermolecular β -sheet structures whereas the depsipeptide analog exhibits the spectrum of an unordered peptide, with a broad band at 1647 cm⁻¹.

We also applied the method to amyloid peptide A β (1–42) **13**, which has been reported to be a difficult sequence for SPPS, because of incomplete couplings that also can be avoided by using Fmoc-amino acid fluorides.¹³



Using an ABI 433A peptide synthesizer and a standard Fmoc-chemistry protocol (N-TBTU, double couplings), A β (27–42) was assembled automatically. The next coupling involving Boc-Ser and the subsequent O-acylation via Fmoc-Gly were carried out manually, and the remainder of the synthesis was completed automatically. Direct use of unprotected Boc-Ser-OH in place of the O-trityl Fmoc analog used in the synthesis of **9** reduces the number of steps required in the generation of the depsipeptide unit. The resulting crude product (depsi isomer) was of excellent quality although it contained a significant by-product A β (26–42), as a result of incomplete O-acylation. Compared with the pseudoproline methodology, a very important advantage of the depsipeptide method results from the fact that the conformation-




Figure 3. Progress of the O→N shift of depsi(22–23) JR 26-mer (rt 15.5 min) to the native JR 26-mer (rt 19.0 min) upon treatment with ammonia over a period of 1 h. See Supplementary data for details.




Figure 4. Comparison of purified depsiA β (1–42) before and after treatment at pH 8.5 (application of the same quantity of both peptides to the HPLC column).

disrupting modification introduced by the depsipeptide unit is still present during chromatographic purification of the deblocked peptide. The suppression of conformation-induced association leads to an increased solubility and narrower peaks for the depsi isomer compared to the amide isomer, thus allowing a much more efficient purification. The HPLC behavior of the two forms is shown in Figure 4.

Acknowledgements

We are indebted to the National Institutes of Health (GM-09706) and the National Science Foundation (NSF CHE-0078971) for support of the work in Amherst.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.tetlet.2004.07.162](https://doi.org/10.1016/j.tetlet.2004.07.162). Experimental details for solid phase syntheses as well as authentic syntheses of various appropriate epimers and all four N \rightarrow O rearrangement products and details of how some were established to be present in test peptide sequences by LC–MS techniques.

References and notes

- Redemann, T.; Jung, G. Peptides 1996. In *Proceedings of the 24th European Peptide Symposium*; Ramage, R., Epton, R., Eds.; Mayflower Scientific Ltd: Kingswinford, UK, 1998; p 749.
- Knorr, R.; Trzeciak, A.; Bannwarth, W.; Gillessen, D. *Tetrahedron Lett.* **1989**, *30*, 1927.
- Carpino, L. A.; El-Faham, A. *J. Am. Chem. Soc.* **1995**, *117*, 5401.
- Carpino, L. A.; El-Faham, A.; Minor, C. A.; Albericio, F. *J. Chem. Soc., Chem. Commun.* **1994**, 201.
- Carpino, L. A.; Ismail, M.; Truran, G. A.; Mansour, E. M. E.; Iguchi, S.; Ionescu, D.; El-Faham, A.; Riemer, C.; Warrass, R. *J. Org. Chem.* **1999**, *64*, 4324.
- If deblocking is difficult the instrument is programmed to add additional deblocking and coupling steps.
- DiFenza, A.; Tancredi, M.; Galoppini, C.; Rovero, P. *Tetrahedron Lett.* **1998**, *39*, 8529.
- (a) Carpino, L. A.; El-Faham, A.; Albericio, F. *Tetrahedron Lett.* **1994**, *35*, 2279; (b) Han, Y.; Albericio, F.; Barany, G. *J. Org. Chem.* **1997**, *62*, 4307; (c) Carpino, L. A.; Imazumi, H.; El-Faham, A.; Ferrer, F. J.; Zhang, C.; Lee, Y.; Foxman, B. M.; Henklein, P.; Hanay, C.; Mugge, C.; Wenschuh, H.; Klose, J.; Beyermann, M.; Bienert, M. *Angew. Chem., Int. Ed.* **2002**, *41*, 441, footnote 24.
- See for example: Fujino, M.; Wakimasu, M.; Shinagawa, S.; Kitada, C.; Yajima, H. *Chem. Pharm. Bull.* **1978**, *26*, 539.
- For the use of acid fluorides for the acylation of polymer supported hydroxyl functions see: Granitza, D.; Beyermann, M.; Wenschuh, H.; Haber, H.; Carpino, L. A.; Truran, G. A.; Bienert, M. *J. Chem. Soc. Chem. Commun.* **1995**, 2223.
- (a) For related work on the use of the O \rightarrow N rearrangement in the development of water-soluble prodrugs see: Oliyai, R.; Stella, V. J. *Bioorg. Med. Chem. Lett.* **1995**, *5*, 2735; (b) Hamada, Y.; Ohtake, J.; Sohma, Y.; Kimura, T.; Hayashi, Y.; Kiso, Y. *Bioorg. Med. Chem.* **2002**, *10*, 4155. While this paper was being prepared for publication Kiso and co-workers (Sohma, Y.; Sasaki, M.; Hayashi, Y.; Kimura, T.; Kiso, Y. *Chem. Commun.* **2004**, 22, 124) published a similar recommendation for the synthesis of difficult peptides; the very first example of the use of related methodology for the synthesis of a difficult peptide was described by Horikawa and Ohfuné and co-workers ((a) Horikawa, M.; Nakajima, T.; Ohfuné, Y. *Synlett* **1998**, 609; (b) Horikawa, M.; Shigeri, Y.; Yumoto, N.; Yoshikawa, S.; Nakajima, T.; Ohfuné, Y. *Bioorg Med. Chem. Lett.* **1998**, *8*, 2027).
- Mutter, M.; Nefzi, A.; Sato, T.; Sun, X.; Wahl, F.; Wöhr, T. *Peptide Res.* **1995**, *8*, 145.
- Milton, S. C. F.; Milton, R. C. D.; Kates, S. A.; Glabe, C. *Letts. Peptide Sci.* **1999**, *6*, 151.